spacer
home > pmps > winter 2018 > the right excipient
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Right Excipient

The global empty hard capsules market is anticipated to increase at a compound annual growth rate of 7.2% and to reach $213 billion in revenues by 2022 (1). Over the past five years, about 12% of all prescription-based (Rx) and overthe- counter (OTC) pharmaceutical products were dosed with hard capsules, according to FDA documentation.

Despite being overlooked in the formulation of prescription drugs, the soft gels market is predicted to grow to $755 million by 2022 (2). This is mainly due to their popularity in the nutraceutical markets and added value in difficult Rx formulations, including very low-dose APIs (< 3mg), potent compounds, hormones and cytotoxic compounds (safe handling), oxygenlabile APIs, and, especially, poorly soluble or permeable APIs. As the market expands and new formulation technologies are adopted, selecting the right ingredient is essential to achieve optimum performance and functionality.

Choosing the Right Excipient

Favoured for its high functional capabilities, gelatine has been used in both hard and soft capsules in the pharma and nutraceutical industry for over 100 years. Capsule manufacturing started in 1834 thanks to gelatine, which has been the safe and only choice for decades. The first commercially feasible gelatine alternative entered the market in 2001: a soft gel shell alternative made of modified starches (hydroxypropyl starch) and carrageenans. Subsequently, hard gelatine capsule alternatives were commercialised, using hydroxypropyl methylcellulose (HPMC) as the main shell ingredient and carrageenans or gellan gum as gelling aids.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Bjorn Vergauwen is Principal Scientist at Rousselot. He currently coordinates R&D projects, aiming to unlock the unmet potential of gelatine. His main expertise relates to the biophysical and biochemical principles underpinning gelatine’s behaviour in food and pharma applications and to its use in dosage forms. Dr Vergauwen has a PhD in biochemistry from Ghent University, Belgium. Before joining Rousselot in 2014, he had several missions as Post-Doctoral Researcher at Ghent University where he conducted research in enzymology and structural biology for 17 years.
spacer
Dr Bjorn Vergauwen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CBIs Global Risk Based Monitoring Event

CBI’s Global Risk Based Monitoring Event is approaching, taking place in London on 13 – 14 September 2018, designed for benchmarking with international peers to gauge RBM performance, efficiencies, implementation and technologies.
More info >>

White Papers

Managing GxP Environmental Systems to Ensure Data Integrity

Vaisala Ltd


More info >>

 
Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement